Nearly 12,000 New Zealanders are set to benefit from major agreements that have been approved by PHARMAC.
Funding for newer and more effective multiple sclerosis treatments has been approved by PHARMAC.
The first funded pharmaceutical treatment for Amyotrophic Lateral Sclerosis (ALS), the most common form of motor neurone disease, will become available from 1 October 2013.
Genetic markers will be used to target a new funded oral treatment for hepatitis C patients from 1 September.
Up to 400 patients a year are likely to live longer as a result of PHARMAC funding two new medicines.
New Zealanders’ use of generic medicines is likely to grow further following the just-completed 2013/14 PHARMAC tender.
DHBs will save another $650,000 a year from lower priced wound care and surgery equipment through a new national PHARMAC agreement with a major medical device supplier.
Both strengths of the Actavis Amoxicillin oral liquid antibiotic have been recalled by the supplier.
PHARMAC has appointed three new members to its Consumer Advisory Committee (CAC), all with strong links to the Pasifika community.
PHARMAC is funding ticagrelor, a new treatment to help prevent heart attacks, from 1 July 2013.
PHARMAC is welcoming the appointment of two new members to the Pharmacology and Therapeutics Advisory Committee.
Patients with severe gout will soon have a new treatment option as PHARMAC will be funding febuxostat (Adenuric) from 1 June 2014.
PHARMAC has announced its intention to test out a contestable fund for high cost medicines for rare disorders, which could be seeking proposals from pharmaceutical companies by the end of 2014.
PHARMAC is asking for people’s views on a proposed new framework for making pharmaceutical funding decisions.
PHARMAC is seeking three new people for its Consumer Advisory Committee.
The number of companies bidding to be suppliers through the PHARMAC tender has grown to its largest size ever.
Improvements in lung cancer treatment are set to continue with a PHARMAC decision to extend funding for erlotinib (Tarceva) from 1 January 2014.
An unreasonably high price means PHARMAC has decided not to approve funding for eculizumab, a treatment for the rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH).
A new agreement with GlaxoSmithKline (GSK) will see two newly listed medicines, improved access to commonly used asthma inhalers, and millions of dollars of savings.
PHARMAC has agreed to fund a new drug to treat a rare and potentially fatal blood disorder.